Answers are grounded in this paper and cite their sources.
A case report highlights severe skin reactions in a mHSPC patient treated with apalutamide, suggesting immediate intervention is needed for serious symptoms.
Rationale: Apalutamide is a generation androgen antagonist for the treatment of metastatic hormone sensitive prostate cancer and non-metastatic castration resistant prostate cancer. Skin adverse reactions caused by apalutamide are mostly rashes and maculopapules. Patient concerns: There are a few reports about exfoliative dermatitis caused by apalutamide. Diagnoses: Severe exfoliative dermatitis induced by apalutamide. Interventions: Gamma globulin, cefoperazone sulbactam sodium, albumin, ebastine, loratadine, hydrocortisone cream, and 3% boric acid lotion. Outcomes: Whole-body skin was red, without exudation, and with a small amount of desquamation. Lessons: The incidence of exfoliative dermatitis due to apalutamide is low but severe, and if a serious adverse skin reaction is suspected, apalutamide needs to be discontinued immediately and treated accordingly.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: